Italia markets closed

Vivos Therapeutics, Inc. (VVOS)

NasdaqCM - NasdaqCM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,5900+0,1050 (+4,23%)
Alla chiusura: 04:00PM EDT
2,6000 +0,01 (+0,39%)
Dopo ore: 05:11PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,4850
Aperto2,5838
Denaro2,5100 x 100
Lettera2,7000 x 100
Min-Max giorno2,4801 - 2,6100
Intervallo di 52 settimane2,3700 - 48,7900
Volume67.455
Media Volume212.106
Capitalizzazione7,724M
Beta (5 anni mensile)7,90
Rapporto PE (ttm)N/D
EPS (ttm)-11,1400
Prossima data utili06 giu 2024 - 10 giu 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A7,22
  • GlobeNewswire

    Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine

    Randomized controlled clinical trial using Vivos’ DNA Oral Appliance Therapy to study the DNA’s impact on OSA versus CPAPLITTLETON, Colo., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company") (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, announced that its flagship daytime-nighttime appliance (DNA) will be tested in a clinic

  • GlobeNewswire

    Vivos Therapeutics Announces Strategic Collaboration in the Middle East-North Africa Region to Support International Expansion

    Vivos Executes Distribution Agreement with Established Dubai-based Sleep Testing Company Subject to Regulatory Approvals, Vivos Could See Revenue From This Collaboration in 2024 LITTLETON, Colo., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary oral appliances for the treatment of breathing-related sleep disorder

  • GlobeNewswire

    Vivos Therapeutics Executes Strategic Agreements with Ormco and On Demand Orthodontist To Provide Spark™ Clear Aligners to Its National Network of Providers

    New Relationships Expected to Add Potentially Significant New Revenue Opportunities for Vivos as well as Airway-Focused Expertise and Potential Cost Savings for Vivos-trained ProvidersLITTLETON, Colo., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary oral appliances for the treatment of breathing-related sleep di